60 Educators providing Education Management courses in Redditch

heartlands education centre

bwh parent education classes

We are Birmingham Women’s and Children’s NHS Foundation Trust – proud to bring together the expertise of Birmingham Children’s Hospital and Birmingham Women’s Hospital. Our Trust is the first of its type in the UK, formed in February 2017 to drive forward our commitment to providing the highest quality, world-class care that women, children and families want, and deserve. Uniting our hospitals means more seamless care; more investment to make greater advances in our specialist treatment and world-leading neo-natal and fetal work. Importantly, it also gives us a greater voice in shaping the future of family-centred care. We have a clear mission, vision and goal for what we want to achieve. Our mission is to provide outstanding care and treatment, to share and spread new knowledge and practice, and to always be at the forefront of what is possible. Our vision is to be a world-leading team, providing world-leading care. Our goal is to be the best place to work and be cared for, where research and innovation thrives, creating a global impact. With more than 641,000 visits from patients each year, we are a busy Trust and pride ourselves on the commitment of our 6,000 strong team, which works tirelessly to provide the very best treatment and support to our women, children and families. Every day our UK and globally-respected surgeons, doctors, nurses, midwives and allied healthcare professionals provide some of the most advanced treatments, complex surgical procedures and cutting-edge research, to improve care today and develop even better care for the future. Home to the country’s leading teaching centres, we’re passionate about nurturing and developing the skills of our present and future workforce, along with investing in the very best training and education to foster life-long learning.

rspca newbrook farm, animal centre, hospital, education centre

the charles hastings education centre

The Charles Hastings Education Centre - The Charles Hastings Education Centre

iqra education trust (uk)

primus education and community development

Primus offers holistic solutions and world-class services for enterprise IT. We specialize in offering the expertise of our highly-qualified consultants from our pool of international and local SAP-certified professionals.We offers one of the best SAP services in Indore & Pune along with other parts of the globe. Our domain knowledge, along with in-depth SAP consulting experience, is considerable. We have gathered a lot of experience in process consulting and adapting business processes to SAP. We are the perfect amalgamation of talent & technology, the best of both the worlds to deliver world-class service to our esteemed clients.

think smart education and training

Think SMART Education and Training aims to provide local individuals with an awareness of the opportunities that are available to them and the support they can get to improve their social skills, education and employability needs. We offer a wide range of academic and vocational courses to suit individuals. We provide flexible learning by offering courses during daytime, evenings and weekends. Our multilingual, qualified and experienced tutors are able to provide creative and innovative lesson planning to adapt to any individuals learning style in order to assist them on their journey. Think SMART Education and Training strives to provide a friendly and professional service by understanding the needs of the local community and the social, cultural, linguistic and educational barriers individuals face. It wants to enable people to fulfil their full potential by allowing them to dictate what their needs are and thus help them set their own personal goals to achieve. Hence this organisation's objective is to work in the heart of the community and for the community to lead in terms of what educational and training support they need.

pcsk9 education and research forum

Reducing low density lipoprotein (LDL) cholesterol is the priority in managing patients with severe dyslipidaemia (cholesterol abnormality) and at high risk of cardiovascular (CV) death and disability. Yet even when treated with potent statins, many patients fail to achieve LDL-cholesterol targets and therefore their risk of accelerated atherosclerosis and CV death remains high. This problem is particularly critical in patients with familial hypercholesterolaemia (FH) (the most commonly occurring genetic condition in the world). People with FH typically have very high LDL cholesterol levels on treatment, and consequently, are at very high risk of premature and sudden CV death, myocardial infarction and stroke. Additionally, some patients are unable to tolerate statins – particularly at higher doses – and, therefore, do not achieve LDL-cholesterol goals. What is the importance of PCSK9? Discovered in 2003,1 PCSK9 is a protein made by the liver which increases the removal of LDL receptors from the surface of liver cells. These LDL receptors are critically important in removal of serum LDL-cholesterol from the circulation. People with so-called ‘gain of function’ PCSK9 mutations over-express PCSK9, and therefore have very high plasma levels of LDL cholesterol and are at very risk of atherosclerosis and CV mortality and morbidity.2 In contrast, people with so-called ‘loss of function’ PCSK9 mutations, have very LDL cholesterol levels and reduced risk for heart disease.3 What is PCSK9 inhibition? Different approaches to lowering PCSK9 are now licensed. These include fully human monoclonal antibodies (alirocumab, evolocumab) and a small-interfering RNA therapy (inclisiran). Trials show that these PCSK9 inhibitors reduce LDL cholesterol levels by about 50-60 percent - a significantly greater effect than that achieved with currently available therapies – either when given alone or in combination. These LDL cholesterol lowering effects have been consistently across a broad group of patients, including those with familial hypercholesterolaemia in clinical trials.4 Which clinical settings will benefit from the availability of PCSK9 inhibitors? These treatments offer the potential to reduce cardiovascular risk in patients whose clinical needs cannot be satisfied by current therapy. These include: Patients with familial hypercholesterolaemia – an inherited disorder of lipid metabolism with a very high risk of early CV death or morbidity, if not diagnosed or treated early Patients who cannot tolerate statins, who therefore remain at high risk of CV events such as heart attacks and strokes Patients with established heart disease who have not achieved LDL-cholesterol goals despite current therapies

ta education and training consultancy

Transforming Teaching and Learning

healthcare education and skills training

HEST Healthcare Education and Skills Training Medical and healthcare education and training at Healthcare Education and Skills Training